YB-2 Inhibitors
Chemical inhibitors of YB-2 operate via various mechanisms to modulate the activity of this protein. Bisindolylmaleimide I acts as a selective inhibitor of protein kinase C (PKC), a family of enzymes that can phosphorylate and regulate numerous proteins, including YB-2. By inhibiting PKC, Bisindolylmaleimide I reduces the phosphorylation events that are critical for YB-2 activation. Similarly, Staurosporine serves as a broad-spectrum protein kinase inhibitor, impacting multiple kinases that could be involved in YB-2's regulation. This inhibition can decrease the phosphorylation state of YB-2, leading to a reduction in its activity.
LY294002 and Wortmannin both target phosphoinositide 3-kinases (PI3K), crucial upstream regulators in cell signaling pathways. By inhibiting PI3K, these chemicals disrupt the PI3K/Akt pathway, which is known to control various cellular functions by phosphorylating target proteins, including YB-2. Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), also impacts the PI3K/Akt pathway. Inhibition of mTOR leads to a downstream reduction in the phosphorylation of proteins that interact with or regulate YB-2. PD98059 and U0126 specifically inhibit MEK, a kinase that phosphorylates and activates ERK. ERK is another kinase that can influence YB-2's function. By blocking the MEK/ERK pathway, PD98059 and U0126 reduce the phosphorylation and subsequent regulatory influence on YB-2. SP600125 and SB203580 target the JNK and p38 MAP kinase pathways, respectively. JNK and p38 MAP kinase are involved in stress and inflammatory responses, and their inhibition can decrease the activity of transcription factors and other regulatory proteins that control YB-2's function. PP2 specifically inhibits Src family kinases, which are part of signaling cascades that can affect YB-2 activity. Lastly, Dasatinib and Gefitinib are inhibitors of tyrosine kinases; Dasatinib broadly targets Src family kinases, while Gefitinib specifically inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. By disrupting these tyrosine kinase signaling pathways, both chemicals can reduce the functional activity of YB-2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a potent and selective inhibitor of protein kinase C (PKC), which is involved in signaling pathways that regulate a wide array of cellular processes including those that could lead to the activation of YB-2. Inhibition of PKC can reduce phosphorylation events that might be necessary for YB-2 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a well-known broad-spectrum inhibitor of protein kinases. Given that many protein kinases are involved in the phosphorylation of proteins that regulate YB-2 activity, staurosporine can inhibit these kinases, thus reducing the phosphorylation and activity of YB-2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, which is an upstream regulator of several signaling pathways including the Akt pathway that can regulate the function of YB-2 by phosphorylation. Inhibition of PI3K leads to reduced Akt activity and thereby decreases the functional activity of YB-2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that operates similarly to LY294002, by blocking the PI3K/Akt pathway. This inhibition can decrease the phosphorylation and subsequent activation of proteins that are involved in the same pathways as YB-2, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and, considering that mTOR is a central component of the PI3K/Akt pathway, its inhibition can decrease the phosphorylation and activation of several proteins that are involved in YB-2's regulation, which leads to the inhibition of YB-2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which in turn inhibits ERK phosphorylation. Since ERK can regulate proteins that interact with YB-2, inhibiting ERK phosphorylation with PD98059 can lead to decreased regulation and functional activity of YB-2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can influence the activity of transcription factors and other proteins that interact with YB-2. Inhibition of JNK with SP600125 can lead to reduced activity of YB-2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, and by inhibiting this kinase, the phosphorylation and activation of downstream proteins that could be involved in YB-2's regulation are decreased, resulting in the functional inhibition of YB-2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents ERK activation. By inhibiting the MEK/ERK pathway, U0126 can reduce the functional activity of proteins that potentially regulate YB-2's function, thereby inhibiting YB-2. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases which are involved in various signaling pathways that can intersect with YB-2's regulatory network. By inhibiting Src kinases, PP2 can reduce the functional activity of YB-2. | ||||||